Compare GENC & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GENC | SIGA |
|---|---|---|
| Founded | N/A | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.6M | 223.8M |
| IPO Year | 1995 | 2016 |
| Metric | GENC | SIGA |
|---|---|---|
| Price | $17.94 | $2.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $17.60 | N/A |
| AVG Volume (30 Days) | 37.1K | ★ 780.9K |
| Earning Date | 02-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 13.24% |
| EPS Growth | ★ 8.08 | N/A |
| EPS | ★ 0.89 | 0.13 |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $25.51 | $224.81 |
| P/E Ratio | ★ $20.22 | $22.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.22 | $2.83 |
| 52 Week High | $18.67 | $9.45 |
| Indicator | GENC | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 74.75 | 34.55 |
| Support Level | $14.30 | N/A |
| Resistance Level | N/A | $4.84 |
| Average True Range (ATR) | 0.80 | 0.14 |
| MACD | 0.39 | -0.00 |
| Stochastic Oscillator | 84.16 | 24.17 |
Gencor Industries Inc and its subsidiaries are a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company's products are manufactured in the United States and sold through a combination of Company sales representatives and independent dealers and agents. The Company has one reporting segment, equipment for the highway construction industry. The Company's principal core products include asphalt pavers, hot mix asphalt plants, combustion systems, and fluid heat transfer systems. It operates in the United States, Canada, and other foreign countries, with the majority of revenue coming from the United States.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.